Silencing of CXCR4 Inhibits Tumor Cell Proliferation and Neural Invasion in Human Hilar Cholangiocarcinoma

Xin-Yu Tan*, Shi Chang†, Wei Liu‡, and Hui-Huan Tang†

Departments of *Emergency, †General Surgery, and ‡Intensive Care Unit, Xiangya Hospital, Central-South University, Changsha, China

Background/Aims: To evaluate the expression of CXC motif chemokine receptor 4 (CXCR4) in the tissues of patients with hilar cholangiocarcinoma (hilar-CCA) and to investigate the cell proliferation and frequency of neural invasion (NI) influenced by RNAi-mediated CXCR4 silencing.

Methods: An immunohistochemical technique was used to detect the expression of CXCR4 in 41 clinical tissues, including hilar-CCA, cholangitis, and normal bile duct tissues. The effects of small interference RNA (siRNA)-mediated CXCR4 silencing were detected in the hilar-CCA cell line QBC939. Cell proliferation was determined by MTT. Expression of CXCR4 was monitored by quantitative real time polymerase chain reaction and Western blot analysis. The NI ability of hilar-CCA cells was evaluated using a perineural cell and hilar-CCA cell coculture migration assay.

Results: The expression of CXCR4 was significantly induced in clinical hilar-CCA tissue. There was a positive correlation between the expression of CXCR4 and lymph node metastasis/NI in hilar-CCA patients (p<0.05). Silencing of CXCR4 in tumor cell lines by siRNA led to significantly decreased NI (p<0.05) and slightly decreased cell proliferation.

Conclusions: CXCR4 is likely correlated with clinical recurrence of hilar-CCA. CXCR4 is involved in the invasion and proliferation of human hilar-CCA cell line QBC939, indicating that CXCR4 could be a promising therapeutic target for hilar-CCA.

Key Words: Hilar cholangiocarcinoma; Neural invasion; CXCR4; RNA interference

INTRODUCTION

Extrahepatic hilar cholangiocarcinoma (hilar-CCA) is a malignant tumor originating from biliary tract epithelial cells and locates most commonly at the hepatic duct bifurcation. It is a relatively rare adenocarcinoma, with an annual incidence of one to two cases per 100,000 in the Western world. In China and Southeast Asia, the incidence of hilar-CCA is relatively higher. Although the annual incidence of this disease in the Western world is lower than that in Asia, the rate of hilar-CCA has significantly risen over the past several decades. Nowadays, it is becoming the most common reason for hepatic tumor-induced death.

Due to its diagnostic difficulty and high fatality rate, hilar-CCA is one of the most extremely destructive cancers. Currently, surgery is the only therapeutic option to offer a cure. However, the post-resection recurrence rate is extremely high and the 5-year survival rate is only 5%. Among various factors in charge of poor survival, neural invasion (NI) represents an important prognostic factor in hilar-CCA, which is thought to be one of the main causes for the high postoperative recurrence rates of hilar-CCA. Survival rate of CCA patients without NI is significantly higher than those with NI, which indicates that NI is highly and positively correlated with the postoperative recurrence and poor prognosis of hilar-CCA. It is further supported by a study using 26 cases of hilar-CCA in the porta hepatis region which revealed that the incidence of NI was 100%, while the proportion of perineural invasion in resected hilar-CCA is around 59% to 88%.

Consequently, the improvement of prognosis of hilar-CCA patients should base on the mechanistic understanding of NI during hilar-CCA pathological progression. Various molecules deemed to play critical roles in regulating the emergence and development of NI were extensively investigated. However, systematic investigations of the mode of NI induced by the interaction between chemokine released from perineural tissue and its receptor on tumor cells have not yet been carried out, although this process represents an important feature in the development of NI.

CXCR motif chemokine receptor 4 (CXCR4) is a stromal cell-derived factor-1 receptor secreted by bone marrow, liver, lung,
and neural cells. The expression of CXCR4 was detected in malignant tumor cells and was positively related with tumor cells migration and hilar-CCA cell invasion. However, the relationship between CXCR4 expression and NIH development in vitro is still largely unknown.

In this study, the expression level of CXCR4 was measured in hilar-CCA patient samples. Then the coculture migration and MTT assay were used to analyze the influence of CXCR4 expression on NIH in hilar-CCA cell line QBC939.

MATERIALS AND METHODS

1. Patients and preparation of tissue specimens

A total of 41 specimens were collected from the Department of General Surgery of Xiangya Hospital between June 2010 and June 2011. All specimens were diagnosed to confirm whether they were hilar-CCA by at least two independent pathologists. Of the 41 specimens, 23 were from hilar-CCA which underwent curative resection, palliative drainage or operative biopsy procedure; with mean age of 61.3 years (range, 53 to 67 years; 13 males vs 10 females). Another 18 specimens were taken from cholangitis patients and liver transplantation patients as the control group. Among which, 14 patients with intrahepatic or/and extrahepatic calculi cholangitis who underwent operative biopsy and cholangiopancreatoscopy (age range, 37 to 41 years, 3 males vs 1 female). All specimens were only used for research purposes. Patients and their family members were informed about the detailed procedures and research purposes of specimen collection before operations. The entire procedure of specimen collection was in conformity with the ethical principles of medicine. In accordance with the guidelines of Central South University, prior informed consent from patients for specimen collection was acquired, and the Ethics Committee of Central South University approval was acquired. Consent of immunostaining as negative (0+), weak (1+), medium (2+), and strong (3+). CXCR4 over-expression was identified only in samples with a score of 2+ or greater.

2. Immunohistochemistry and evaluation

The expression of CXCR4 in hilar-CCA, cholangitis or normal bile duct tissue specimens was detected immunohistochemically using Histostain-SP kits (Boster, Wuhan, China) according to the manufacturer’s recommendations. Briefly, specimen sections were deparaffinized, placed in 0.01 mol/L citrate buffer (pH 6.0), heated for 15 minutes to unmack the antigens, and then incubated in methanol with 3% hydrogen peroxide for 15 minutes to inactivate endogenous peroxidase activity. After washing with phosphate-buffered saline, sections were incubated with protein block serum (Boster) for 15 minutes to block nonspecific reaction and were subsequently incubated with primary anti-CXCR4 antibody (dilution 1:50; Boster) at 4°C overnight. After that, sections were treated with biotinylated secondary antibody and peroxidase-conjugated streptavidin for 20 minutes at room temperature and then washed with distilled water. The CXCR4 immunostaining was visualized with hematoxylin. Sections were then scanned using light microscope.

Three independent pathologists were invited to evaluate the specimen sections single-blindly. The intensity and staining percentage of CXCR4 expression were assessed. The expression of CXCR4 was semiquantitatively scored by the intensity of immunostaining as negative (0+), weak (1+), medium (2+), and strong (3+). CXCR4 over-expression was identified only in samples with a score of 2+ or greater.

3. Cell lines and cell culture

Hilar-CCA cell line QBC939 was kindly provided by Professor Wang from the Third Military Medical University, Chongqing, China. Hilar-CCA cell line SNU-1196 and human perineurial cell line human perineural cells; cell line code of sciencell USA were purchased from Korean Cell Bank and ScienCell Research Laboratories (http://www.sciencellonline.com; Catalog no. 1710, San Diego, CA, USA), respectively.

Hilar-CCA cell lines (QBC939 and SNU-1196) were maintained in RPMI 1640 (Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum and penicillin-streptomycin-glutamine (Life Technologies). HPC was cultured according to the instructions of ScienCell Research Laboratories.

Table 1. The Sequences of the Designed CXC Motif Chemokine Receptor 4-Specific Small Interference RNAs

| siRNA    | Sequence                        |
|----------|---------------------------------|
| siRNA370 | 5'-GGGACUAUAGUCGUAAGAATT UUCGAGGAGCAUAGUCCTT-3' |
| siRNA960 | 5'-CGGUGUAGUCGUAAGAATT UUCGAGGAGCAUAGUCCTT-3' |
| siRNA1609| 5'-CGGUGUAGUCGUAAGAATT UUCGAGGAGCAUAGUCCTT-3' |
| Negative | 5'-UUCGAGGAGCAUAGUCCTT-3'       |
| Positive | 5'-GUAUCGAGGAGCAUAGUCCTT-3'     |
| FAM-control: 5'-UUCGAGGAGCAUAGUCCTT-3' |
4. CXCR4-small interference RNA construction and transfection to Hilar-CCA cell lines

Small interference RNA (siRNA) targeting CXCR4 (GeneBank no. NM_003467) or nonspecific control sequences (Table 1) were designed and purchased from GenePharma Corporation (Shanghai, China). Transient transfection for CXCR4-siRNA to human hilar-CCA cell lines QBC939 and SNU-1196 was performed using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions.

5. Measurement of CXCR4 protein and mRNA expression in hilar-CCA cell lines

CXCR4 protein expression in QBC939 was evaluated by Western blot analysis with three replicates. After washing with phosphate-buffered saline for three times, QBC939 and SNU-
1196 cells were lysed in lysis buffer (mammalian protein extraction reagent; Pierce, Rockford, IL, USA) and centrifugated at 15,300 rpm for 15 minutes at 4°C. A total of 25 μg of protein was used as a sample. The electrophoresis experiment was performed in 10% sodium dodecyl sulfate-polyacrylamide gel. The CXCR4 protein was electrophoretically transferred onto a nitrocellulose membrane, and was then incubated in an ice bath with CXCR4 primary antibody (Catalog no. ab2074; Abcam HK) at voltage-stabilizer (Life Technologies). Finally, the CXCR4 protein was detected by secondary antibody conjugated to peroxidase (Zhongshan Golden Bridge Biotechnology, Beijing, China) and benzidine reaction.

The expression of CXCR4 mRNA was detected using quantitative real-time PCR assay with three replicates. Total RNA was extracted from cell lines QBC939 by Trizol reagent (Life Technologies). Quantitative PCR assay was performed by prepared CXCR4 and glyceraldehyde phosphate dehydrogenase (GAPDH) specific primers using ABI Prism 7700 sequence detection system (PE Applied Biosystems, Warrington, UK). The CXCR4 and GAPDH primers were as follows: 5'-CGCGGCCAAGCTGTACCTTT-3' (CXCR4, forward); 5'-GAAGCCCAACATAGACCACCT-3' (CXCR4, reverse); 5'-CAATGACCCCTTCATTGACC-3' (GAPDH, forward); 5'-GACGCCAACATAGACGTACTTT-3' (CXCR4, reverse). PCR reaction was done with the TaqMan Universal PCR Master Mix (PE Applied Biosystems). Cycling conditions were: 1 cycle of 15 seconds at 95°C, and 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. CXCR4 was normalized (ΔCt) to GAPDH by subtracting the cycle threshold (Ct) value of GAPDH from the Ct value of CXCR4.

6. Perineural cell and hilar-CCA cell coculture migration assay

The NI ability of hilar-CCA was evaluated by hilar-CCA and perineural cells coculture migration assay with three replicates. Hilar-CCA cells was cocultured with perineural cells using Matrigel invasion chamber purchased from BD Biocoat Cellware (San Jose, CA, USA) as previously reported.24 Medium (0.5 μL) containing 5×10^3 hilar-CCA cells was added to the upper chamber, and 0.5 mL of either medium alone or medium containing 1 to 2×10^5 HPC cells was added to the lower chamber. Chambers were then incubated for 48 hours at 37°C under 5% CO₂. After experiment, hilar-CCA cells on the upper surface were removed, and cells that had migrated to the lower surface were stained by hematoxylin. The ratio of the migrated cells number in the siRNA interference group or of the migrated cells number in the control group was identified as migration index.

7. Apoptotic measurement using Hoechst and propidium iodide double staining

To further confirmed the apoptotic measurement by cytomtery, hilar-CCA cells after CXCR4-siRNA treatments were stained with Hoechst 33342 (5 μg/mL; Sigma, St. Louis, MO, USA) and propidium iodide (PI; 5 μg/mL; Sigma) in the medium to label live cells for 15 minutes. Cells with PI positive staining were calculated against the total cell number shown by Hoechst staining.

8. Hilar-CCA proliferation assay

QBC939 cells were seeded onto 96-well plates (1×10^4 cells per well). The cell proliferation was assessed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-tetrazolium (MTT) assay (Promega, Madison, WI, USA). Plates were incubated for 24 hours at 37°C under 5% CO₂ for approximately 3 hours. After dissolve with dimethyl sulfoxide, the absorbance of cellular MTT metabolite was detected at 570 nm wavelength. Mean optical density value was documented as result, and the MTT assay was performed for three times to calculate the cell proliferation rate.

9. Statistical analysis

Statistical analysis was performed using analysis of variance, followed by the Turkey test using SigmaStat software (Systat Software Inc., San Jose, CA, USA). Results were considered statistically significant at least p<0.05.

RESULTS

1. Overexpression of CXCR4 correlates to NI and lymph node metastasis in hilar-CCA tissues

Expression pattern of CXCR4 protein in clinical samples was analyzed immunohistochemically. Results showed that CXCR4

| Table 2. | CXCR4 Motif Chemokine Receptor 4 (CXCR4)-Overexpression-Induced Phenotypes in Human Cholangiocarcinoma Cells and the Comparison of Clinicopathological Variables Dependent on the CXCR4 mRNA Expression Level |
|-----------|---------------------------------------------------------------|
| CXCR4 mRNA | Mean±SE | p-value |
| Hematoidin concentration | >171 μM (n=15) | 51.7±21.3 | >0.05 |
| Tumor diameter | >2 cm (n=15) | 68.9±11.1 |
| Liver metastasis | Positive (n=15) | 66.7±15.8 |
| Lymph node invasion | Positive (n=15) | 88.1±17.8 | <0.05 |
| Tumor differentiation | Positive (n=15) | 111.4±21.6 | <0.05 |
| SE, standard error |

Tan XY, et al: CXCR4 in Human Hilar-CCA
was primarily expressed in membrane, cytoplasm, and/or biliary luminal surface. CXCR4 in 15 out of 23 (65.22%) hilar-CCA cases were detected as overexpression, five out of 14 (35.71%) cholangitis cases were detected as normal expression, whereas in all (n=15) of the normal bile duct tissues were detected as nonexpression, with a statistically significant difference (p=0.0001) (Fig. 1).

These findings also significantly correlate with clinicopathological features such as lymph node metastasis and NI. Among the 15 CXCR4 overexpression cases (indicated by quantitative real-time PCR results), 11 cases (73.3%) showed high hematoxin concentration (above 171 μmol/L), 13 (86.7%) cases showed bigger tumor diameters (above 2 cm) than those detected in CXCR4-normal expression cases (equal or less than 2 cm) and 12 cases (80.0%) showed liver metastasis and tumor differentiation, whereas there were only three (37.5%) with liver metastasis and four (50%) with tumor differentiation in eight cases of CXCR4 nonoverexpression. In addition, 14 of 15 (93.3%) showed remarkably high association between CXCR4 overexpression with lymph node invasion and NI with a statistically significant difference (p<0.05) (Table 2). Obviously, at the histological level, there was a significant correlation between CXCR4 overexpression and tumor development.

2. siRNA-CXCR4 suppresses CXCR4 expression in QBC939 cells

CXCR4 mRNA expression was examined in a panel of two hilar-CCA cell lines QBC939 and SHU-1196 by real-time PCR. Results showed that the cell line QBC939 had the highest expression level of CXCR4 mRNA (data not shown). In this regard, the cell line QBC939 was chosen for following studies.

QBC939 was effectively transfected with CXCR4 siRNA oligos for 48 hours by using Lipofectamine 2000 transfection kit. Transfection efficiency was detected by fluorescent assay, which

![Fig. 2. Small interference RNA plasmid vector transfection of QBC939 cells detected by fluoroscopic examination (×400). (A, B) Representative fluorescent images of CXCR4 siRNA 370 and 960, respectively. (C, D) Representative bright field images of CXCR4 siRNA 370 and 960, respectively.](image-url)
showed 10% efficiency after 48-hour transfection (Fig. 2). The silencing effects of three different CXCR4 specific siRNAs in QBC939 cells were evaluated using real-time reverse transcription-PCR and Western blot siRNA-CXCR4 transfectants showed a remarkably decreased expression of CXCR4. Inhibition ratio of 86.42%, 76.63%, and 69.20% for CXCR4 mRNA by using siRNA370, siRNA960, and siRNA1609 were achieved respectively when compared to untreated QBC939 cells, while siRNA-control showed no effects (Fig. 3A). Western blot analysis confirmed the down-regulation of CXCR4 protein by transfection of siRNA expressing vector (Fig. 3B).

Activated p21-activated kinase (aPak) is an important tissue specific regulator of p53 in many tissues (e.g., tumor tissues). It inhibits p53 activity by interacting with ataxia-telangiectasia mutated protein kinase to prevent cell apoptosis. Western blot result showed the aPak expression level was depressed since CXCR4 was silenced by its specific siRNA (Fig. 4). In addition, the cell cycle phase observations provided direct evidence that CXCR4 inhibition increased the apoptotic rate (AR) of hilar-CCA cells, probably through the action of aPak. The proportion of cells that have undergone apoptosis increased from 2.46% of QBC939 to 15.16% of QBC939/siRNA-CXCR4 cells. The AR of QBC939 cells and QBC939/siRNA-control cells was 7.44% and 8.97%, respectively (Fig. 5). Apoptosis evaluation using Hoechst and PI further confirmed the AR results from cytometry (Table 3).

3. CXCR4 silencing reduces the N by coculture of perineural cells and QBC939 cells in vitro

The results showed that in cocultured group during 24 to 72-hour incubation for QBC939 and QBC939/siRNA-control cells had a similar ability to pass through the Matrigel coated filter, because the numbers of invading cells were roughly equal (Fig. 6C-F). The number of QBC939/siRNA-J70 cells (25.60±3.28) passing through the Matrigel was significantly lower than the numbers of QBC939 (55.80±5.03) and QBC939/siRNA-control cells (p<0.01). After 72-hour coculture, a more than 300% increase of migration between QBC939/siRNA- CXCR4 cells and QBC939/siRNA-control cells was observed (Fig. 6A-D).

4. CXCR4 silencing reduces the proliferation of QBC939 cells

The proliferation of QBC939, QBC939/siRNA-control, and QBC939/siRNA-CXCR4 was determined respectively. As shown in Table 3, compared with QBC939, the proliferation of QBC939/siRNA-CXCR4 was significantly inhibited to 87.07% (QBC939/siRNA1609), 85.25% (QBC939/siRNA960), and 84.63% (QBC939/siRNA370) at 72 hours, respectively. There was no significant difference among those siRNA treatments (p>0.05) (Fig. 7).

DISCUSSION

Recent direct evidence shows that overexpression of CXCR4 promotes cancer cell progression and metastasis in several types of tumor, such as pancreatic cancer, breast cancer, colorectal cancer, and bile duct cancer. In this study, statistical analysis of immunohistochemistry data showed an obvious positive relationship between the over-expression of CXCR4 and the incidence of hilar-CCA. Down-regulation of endogenous CXCR4 by siRNA inhibition caused reduction of tumor diameter (data not shown), cancer cell apoptosis and decreased motility and invasion potentials. CXCR4 expression was effectively inhibi-
The repression of CXCR4 alone is not sufficient to explain the decreased NI and lymph node invasion. The possible involvement of matrix metalloproteinases (MMPs), glial cell line-derived neurotrophic factor, and L1 cell adhesion molecule in tumor tissue that control perineural invasion has
been reported by Chinni et al.,23 and Ben et al.24 Particularly, MMPs was identified as one of triggers to introduce tumor migration by hydrolyzing extracellular matrix. Down-regulation of CXCR4 expression in hilar-CCA cells reduced the secretion of MMPs, thus inhibited the invasion ability of hilar-CCA cells through the reconstituted basement membrane in vitro.

The effect of CXCR4 silencing on the proliferation of QBC939 cells was examined. The proliferation potential of QBC939/siRNA-CXCR4 cells was slightly suppressed when compared with that of the control QBC939 cells. Activation of CXCR4 was reported to promote the proliferation of gastric cancer,25 pancreatic cancer,26 and squamous cell carcinoma in head and neck.26 Activated CXCR4 is a heterotrimeric complex with G-protein, which may activate phosphoinositide-3 kinase and phospholipase C, to further activate p21-activated kinase (PAK), leading to tumor cell polarization and adhesion for migration.27,28 However, proliferation potential depression induced by CXCR4 overexpression was found in intrahepatic and hilar-CCA cell lines.28 This suggests that CXCR4 obtained different roles for proliferation among different tumor cells. In conclusion, this study showed that the CXCR4 is probably correlated with the incidence of hilar-CCA clinically because silencing of CXCR4 by its specific RNAi inhibited invasion and lymph node metastasis of human hilar-CCA cell line QBC939 in vitro. Our findings suggested that CXCR4 might be a promising target for CCA treatment against NI and lymph node metastasis.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This study was supported by the Freedom Explore Program of Central South University (2011QNZT162).

REFERENCES

1. Carranga MT, Beason DE. Liver, gallbladder, extrahepatic bile duct, and pancreas. Cancer 1995;75 Suppl:171-190.
2. Shinb Y, El-Seng HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115-125.
3. Delivein MG, Cunningham SC, Cammisa JI, et al: Cholangiocarcinoma: thirty-five-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-762.
4. Ramaccato G, Niggi G, Bellagamba R, et al: Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg 2007;76:1260-1268.
5. Zhang BY, Lu Y, Dong Q, Sun CD, Mu P. Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma. Am J Med Sci 2010;339:221-224.
6. Fung DY, Steel J, Vazquez T, et al: Initial presentation and management of hilar and perihilar cholangiocarcinoma: a node-positive status or potential margin-positive result a contraindication to resection? Ann Surg Oncol 2009;16:220-2215.
7. Shen FZ, Zhang BY, Feng YJ, et al: Current research in perineural invasion of cholangiocarcinoma. J Exp Clin Cancer Res 2010;29:24.
8. Zhe Z, Klee J, Kayed R, et al: Nerve growth factor and enhancement of proliferation, invasion, and tumorogenicity of pancreatic cancer cells. Mol Carcinog 2002;35:128-147.
9. Bhuyian MR, Himun Y, Kamaya J, et al: Clinicopathologic studies on perineural invasion of bile duct cancer. Ann Surg 1992;215:344-349.
10. Schreiber SC, Gielis K, Kartika C, et al: Polyclonalized IFN-repressor E-cadherin-medlated cell-cell adhesion in pancreatic tumor cells. Gastroenterology 2000;119:1555-1566.
11. Gluckman M, Gilles C, Czodybos M, et al: Cloning and characterization of SDF-1gamma, a novel SDF-1 chemokine transcript with developmentally regulated expression in the nervous system.
12. Katayama A, Ogino T, Bandoh H, Honaka S, Hambuchi Y. Expression of CXCR4 and its down-regulation by IFN-γ in head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:2937-2946.

13. Ukita D, Bégum NM, Tomizuka Y, et al. Acquisition of lymph node, but not distant metastatic potential, by the overexpression of CXCR4 in human oral squamous cell carcinoma. Lab Invest 2004;84:1538-1546.

14. Marchesi F, Moni P, Leone B, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004;64:4420-4427.

15. Leelawat K, Leelawat S, Narong S, Hongeng S. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol 2007;13:1561-1568.

16. Yu J, Liu L, Ma J, Huang Q, Ren Y. Analysis of factors influencing prognosis of patients with lung carcinoma without resection. J Hepatobiliary Surg 2008;4:181-183.

17. Koo YJ, Youn KA, Kim UI, et al. Establishment and characterization of six human biliary tract cancer cell lines. Br J Cancer 2002;87:187-193.

18. Meador M, Khanum C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol 2009;41:1452-1462.

19. Holland JD, Kochetkova M, Akekwotchai C, Dethy MR, Lopez A, McColl SR. Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 2006;66:4117-4124.

20. Wang SC, Lin JK, Wang HS, Yang SH, Li AF, Chang SC. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 2010;25:1185-1191.

21. Okamoto K, Tajima H, Nakamura S, et al. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma. Int J Oncol 2012;41:572-582.

22. Ouyang L, Shi Z, Zhao S, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 2012;45:487-498.

23. Chunyi SR, Sivagnan S, Dang Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006;66:22-41.

24. Beu QW, Wang JC, Liu J, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010;17:2112-2121.

25. Zhao BC, Wang ZJ, Mao WZ, et al. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol 2011;17:2389-2396.

26. Katayama A, Ogino T, Bandoh H, Honaka S, Hambuchi Y. Expression of CXCR4 and its down-regulation by IFN-γ in head and neck squamous cell carcinoma. Clin Cancer Res 2005;11:2937-2946.

27. Barbieri F, Bajetto A, Florio T. Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol 2010;2010:426956.

28. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927-2931.